VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a biotechnology company targeting innovative therapies for serious...
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pascal Biosciences (TSXV:PAS) (OTCPink:PSCBF) (FSE:6PB), a biotechnology company targeting innovative therapies for serious...
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:...
VANCOUVER, British Columbia and SEATTLE and DAEJON, Korea, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today...
VANCOUVER, British Columbia, and SEATTLE, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may...
VANCOUVER, British Columbia and SEATTLE, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”). Pascal announces that Dr. Patrick Gray, CEO, will...
Vancouver, BRITISH COLUMBIA and SEATTLE, May 29, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today...
VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today...
VANCOUVER, British Columbia and SEATTLE, April 23, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約